Provides diagnostic solutions for lung disease, utilizing multi-omics and AI to personalize patient care.
Biodesix, Inc. functions as a pioneering diagnostic solutions company rooted in data-driven approaches within the United States. Specializing in advanced lung cancer diagnostics, the company's flagship offerings include the Nodify XL2 and Nodify CDT tests, integral components of the Nodify Lung Nodule Risk Assessment strategy. These blood-based tests are pivotal in assessing lung cancer risk and aiding physicians in determining the appropriate treatment paths, as well as reclassifying malignancy risks in patients with suspicious lung nodules.
Moreover, Biodesix, Inc. provides GeneStrat ddPCR and VeriStrat tests for lung cancer diagnosis, essential for detecting mutations within tumors and evaluating the patient's immune system status to inform prognosis and guide treatment decisions. The company also offers the GeneStrat NGS (Next-Generation Sequencing) test, a rapid 72-hour blood-based NGS solution. In collaboration with Bio-Rad Laboratories, Inc., Biodesix delivers the Bio-Rad SARS-CoV-2 ddPCR COVID-19 Test as part of its Biodesix WorkSafe program, alongside the Platelia SARS-CoV-2 Total Ab test, designed to detect B-cell immune responses to SARS-CoV-2, indicating recent or prior infections.
Beyond diagnostics, Biodesix, Inc. extends its expertise to diagnostic and clinical research services, catering particularly to biopharmaceutical companies. The company is actively engaged in the discovery, development, and commercialization of companion diagnostics, reinforcing its commitment to enhancing patient outcomes through innovative diagnostic solutions. Founded in 2005 and originally known as Elston Technologies, Inc., Biodesix, Inc. is headquartered in Boulder, Colorado, strategically positioned at the forefront of diagnostic innovation in oncology and infectious diseases.